Tharimmune (THAR) Competitors $2.11 +0.08 (+3.94%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends THAR vs. CING, NERV, SPRB, NRSN, HCWB, FLGC, SNSE, IMNN, BGXX, and AIMShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Cingulate (CING), Minerva Neurosciences (NERV), Spruce Biosciences (SPRB), NeuroSense Therapeutics (NRSN), HCW Biologics (HCWB), Flora Growth (FLGC), Sensei Biotherapeutics (SNSE), Imunon (IMNN), Bright Green (BGXX), and AIM ImmunoTech (AIM). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Cingulate Minerva Neurosciences Spruce Biosciences NeuroSense Therapeutics HCW Biologics Flora Growth Sensei Biotherapeutics Imunon Bright Green AIM ImmunoTech Tharimmune (NASDAQ:THAR) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment. Does the media refer more to THAR or CING? In the previous week, Tharimmune's average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score. Company Overall Sentiment Tharimmune Neutral Cingulate Neutral Do insiders & institutionals have more ownership in THAR or CING? 1.2% of Tharimmune shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 2.4% of Tharimmune shares are held by insiders. Comparatively, 17.1% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend THAR or CING? Tharimmune presently has a consensus price target of $17.00, suggesting a potential upside of 705.69%. Cingulate has a consensus price target of $12.00, suggesting a potential upside of 148.96%. Given Tharimmune's stronger consensus rating and higher probable upside, equities analysts plainly believe Tharimmune is more favorable than Cingulate.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Cingulate 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more volatility and risk, THAR or CING? Tharimmune has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.84, indicating that its stock price is 184% less volatile than the S&P 500. Which has stronger earnings & valuation, THAR or CING? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$9.32MN/AN/ACingulateN/AN/A-$23.53MN/AN/A Is THAR or CING more profitable? Tharimmune's return on equity of -167.63% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -167.63% -130.18% Cingulate N/A -570.20%-236.15% Does the MarketBeat Community favor THAR or CING? Cingulate received 7 more outperform votes than Tharimmune when rated by MarketBeat users. However, 100.00% of users gave Tharimmune an outperform vote while only 75.00% of users gave Cingulate an outperform vote. CompanyUnderperformOutperformTharimmuneOutperform Votes2100.00% Underperform VotesNo VotesCingulateOutperform Votes975.00% Underperform Votes325.00% SummaryTharimmune beats Cingulate on 7 of the 11 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.08M$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A10.0188.8317.53Price / SalesN/A335.611,282.2680.28Price / CashN/A22.6336.6032.90Price / Book0.015.084.964.69Net Income-$9.32M$154.90M$117.89M$224.57M7 Day Performance7.11%2.59%2.75%3.33%1 Month Performance1.93%1.52%3.63%5.33%1 Year Performance-64.12%5.49%27.27%22.97% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune2.946 of 5 stars$2.11+3.9%$17.00+705.7%-65.5%$4.08MN/A0.002CINGCingulate2.4404 of 5 stars$4.63-3.7%$12.00+159.2%+5.3%$14.87MN/A0.0020NERVMinerva Neurosciences3.3536 of 5 stars$2.12-2.3%$5.00+135.8%-71.2%$14.83MN/A-4.829Analyst ForecastNews CoverageGap DownSPRBSpruce Biosciences4.0286 of 5 stars$0.36-4.0%$3.90+997.7%-84.7%$14.68M$7.10M-0.3820Positive NewsNRSNNeuroSense Therapeutics0.7102 of 5 stars$1.04-0.4%N/A+13.5%$14.16MN/A-1.2210HCWBHCW Biologics1.6141 of 5 stars$0.36-1.9%N/A-66.4%$13.77M$3.50M-0.3640FLGCFlora Growth2.1717 of 5 stars$0.93-3.2%$5.00+438.2%-43.5%$13.40M$64.15M0.00280SNSESensei Biotherapeutics4.2792 of 5 stars$0.53+3.5%$4.33+717.0%-33.1%$13.34MN/A-0.4540IMNNImunon1.9869 of 5 stars$0.92+1.8%$20.50+2,137.7%+60.2%$13.28M$500,000.00-0.4830Short Interest ↑BGXXBright GreenN/A$0.07+1.0%N/A-68.7%$13.19MN/A-1.152AIMAIM ImmunoTech1.8527 of 5 stars$0.20-4.7%$2.75+1,242.1%-49.1%$13.07M$190,000.00-0.4420 Related Companies and Tools Related Companies Cingulate Competitors Minerva Neurosciences Competitors Spruce Biosciences Competitors NeuroSense Therapeutics Competitors HCW Biologics Competitors Flora Growth Competitors Sensei Biotherapeutics Competitors Imunon Competitors Bright Green Competitors AIM ImmunoTech Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:THAR) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THAR Stock Alerts